2024 Q2 Form 10-Q Financial Statement
#000162828024021945 Filed on May 09, 2024
Income Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| Revenue | $43.65M | $32.61M | $40.13M |
| YoY Change | -22.58% | -18.74% | -34.96% |
| Cost Of Revenue | $17.05M | $11.61M | $19.48M |
| YoY Change | -1.37% | -40.44% | -37.84% |
| Gross Profit | $26.60M | $21.00M | $20.64M |
| YoY Change | -31.95% | 1.74% | -31.99% |
| Gross Profit Margin | 60.94% | 64.41% | 51.44% |
| Selling, General & Admin | $26.92M | $25.44M | $25.22M |
| YoY Change | -0.44% | 0.86% | -43.1% |
| % of Gross Profit | 101.19% | 121.12% | 122.18% |
| Research & Development | $7.647M | $9.731M | $19.69M |
| YoY Change | -62.14% | -50.57% | -55.09% |
| % of Gross Profit | 28.75% | 46.33% | 95.36% |
| Depreciation & Amortization | $9.410M | $364.0K | $9.409M |
| YoY Change | 4.43% | -96.13% | -0.2% |
| % of Gross Profit | 35.37% | 1.73% | 45.58% |
| Operating Expenses | $35.33M | $35.94M | $45.58M |
| YoY Change | -26.54% | -21.16% | -48.7% |
| Operating Profit | -$8.725M | -$14.94M | -$24.94M |
| YoY Change | -3.01% | -40.11% | -57.37% |
| Interest Expense | -$2.149M | -$2.498M | -$1.561M |
| YoY Change | 30.88% | 60.03% | -69.16% |
| % of Operating Profit | |||
| Other Income/Expense, Net | -$39.00K | $95.00K | $282.0K |
| YoY Change | 290.0% | -66.31% | -75.13% |
| Pretax Income | -$8.582M | -$17.99M | -$26.22M |
| YoY Change | -23.18% | -31.4% | -58.0% |
| Income Tax | |||
| % Of Pretax Income | |||
| Net Earnings | -$8.582M | -$17.99M | -$26.22M |
| YoY Change | -23.18% | -31.4% | -58.0% |
| Net Earnings / Revenue | -19.66% | -55.16% | -65.34% |
| Basic Earnings Per Share | -$0.04 | -$0.09 | -$0.14 |
| Diluted Earnings Per Share | -$0.04 | -$0.09 | -$0.14 |
| COMMON SHARES | |||
| Basic Shares Outstanding | 209.6M shares | 209.4M shares | 184.2M shares |
| Diluted Shares Outstanding | 209.7M shares | 205.0M shares | 184.8M shares |
Balance Sheet
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $39.50M | $41.96M | $56.95M |
| YoY Change | -26.27% | -26.32% | -67.37% |
| Cash & Equivalents | $39.50M | $41.96M | $57.00M |
| Short-Term Investments | |||
| Other Short-Term Assets | $7.329M | $4.813M | $25.38M |
| YoY Change | -69.96% | -81.04% | 5.22% |
| Inventory | $23.87M | $25.53M | $20.60M |
| Prepaid Expenses | |||
| Receivables | $29.77M | $26.62M | $17.78M |
| Other Receivables | $0.00 | $0.00 | $0.00 |
| Total Short-Term Assets | $112.1M | $112.9M | $120.7M |
| YoY Change | -5.36% | -6.44% | -60.12% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $2.895M | $3.265M | $4.816M |
| YoY Change | -34.49% | -32.21% | -25.34% |
| Goodwill | $59.00M | $59.00M | $55.10M |
| YoY Change | 0.0% | 7.08% | 0.0% |
| Intangibles | $18.02M | $27.03M | |
| YoY Change | -66.67% | ||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $17.78M | $11.79M | $5.238M |
| YoY Change | 431.03% | 125.14% | -86.71% |
| Total Long-Term Assets | $108.1M | $112.5M | $156.1M |
| YoY Change | -20.08% | -27.93% | -32.89% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $112.1M | $112.9M | $120.7M |
| Total Long-Term Assets | $108.1M | $112.5M | $156.1M |
| Total Assets | $220.2M | $225.5M | $276.9M |
| YoY Change | -13.21% | -18.56% | -48.29% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $10.11M | $11.88M | $12.58M |
| YoY Change | -14.17% | -5.53% | -35.39% |
| Accrued Expenses | $53.90M | $53.91M | $46.37M |
| YoY Change | -4.45% | 16.27% | -57.72% |
| Deferred Revenue | $43.30M | $695.0K | $0.00 |
| YoY Change | -100.0% | ||
| Short-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Long-Term Debt Due | $0.00 | $0.00 | $24.00M |
| YoY Change | -100.0% | -100.0% | -75.47% |
| Total Short-Term Liabilities | $107.3M | $66.49M | $82.94M |
| YoY Change | 16.4% | -19.84% | -67.33% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $38.03M | $30.15M | $26.30M |
| YoY Change | 105.73% | 14.64% | |
| Other Long-Term Liabilities | $6.557M | $6.771M | $12.64M |
| YoY Change | -61.75% | -46.44% | -83.74% |
| Total Long-Term Liabilities | $44.59M | $36.92M | $38.94M |
| YoY Change | 25.15% | -5.2% | -49.91% |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $107.3M | $66.49M | $82.94M |
| Total Long-Term Liabilities | $44.59M | $36.92M | $38.94M |
| Total Liabilities | $254.0M | $252.7M | $291.2M |
| YoY Change | -9.47% | -13.21% | -42.81% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$1.636B | -$1.627B | -$1.579B |
| YoY Change | 2.54% | 3.03% | 3.7% |
| Common Stock | $1.602B | $1.600B | $1.565B |
| YoY Change | 2.14% | 2.23% | 1.03% |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | -$33.75M | -$27.26M | -$14.35M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $220.2M | $225.5M | $276.9M |
| YoY Change | -13.21% | -18.56% | -48.29% |
Cashflow Statement
| Concept | 2024 Q2 | 2024 Q1 | 2023 Q1 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$8.582M | -$17.99M | -$26.22M |
| YoY Change | -23.18% | -31.4% | -58.0% |
| Depreciation, Depletion And Amortization | $9.410M | $364.0K | $9.409M |
| YoY Change | 4.43% | -96.13% | -0.2% |
| Cash From Operating Activities | -$10.07M | -$19.43M | -$17.54M |
| YoY Change | -377.38% | 10.8% | -18.88% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $29.00K | $0.00 | |
| YoY Change | -100.0% | ||
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | |||
| YoY Change | |||
| Cash From Investing Activities | -$29.00K | $0.00 | $0.00 |
| YoY Change | -100.0% | ||
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | |||
| YoY Change | |||
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 7.640M | $18.48M | -$15.97M |
| YoY Change | -195.5% | -215.71% | -133.58% |
| NET CHANGE | |||
| Cash From Operating Activities | -10.07M | -$19.43M | -$17.54M |
| Cash From Investing Activities | -29.00K | $0.00 | $0.00 |
| Cash From Financing Activities | 7.640M | $18.48M | -$15.97M |
| Net Change In Cash | -2.455M | -$957.0K | -$33.50M |
| YoY Change | -43.83% | -97.14% | -229.81% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$10.07M | -$19.43M | -$17.54M |
| Capital Expenditures | $29.00K | $0.00 | |
| Free Cash Flow | -$10.10M | -$17.54M | |
| YoY Change | -378.18% | -19.31% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2024Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-27258000 | usd |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent | |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
|
http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent | |
| CY2024Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
32607000 | usd |
| CY2023Q1 | us-gaap |
Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
|
40005000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
|
2594000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Service Excluding Depreciation Depletion And Amortization
CostOfGoodsAndServiceExcludingDepreciationDepletionAndAmortization
|
11178000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
|
9011000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Goods And Services Sold Amortization
CostOfGoodsAndServicesSoldAmortization
|
9011000 | usd |
| CY2024Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
11605000 | usd |
| CY2023Q1 | us-gaap |
Cost Of Revenue
CostOfRevenue
|
20189000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
9731000 | usd |
| CY2023Q1 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
19686000 | usd |
| CY2024Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
25438000 | usd |
| CY2023Q1 | us-gaap |
Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
|
25053000 | usd |
| CY2024Q1 | akba |
License Expense
LicenseExpense
|
711000 | usd |
| CY2023Q1 | akba |
License Expense
LicenseExpense
|
568000 | usd |
| CY2024Q1 | us-gaap |
Restructuring Charges
RestructuringCharges
|
58000 | usd |
| CY2023Q1 | us-gaap |
Restructuring Charges
RestructuringCharges
|
106000 | usd |
| CY2024Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
35938000 | usd |
| CY2023Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
45413000 | usd |
| CY2024Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-14936000 | usd |
| CY2023Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-25597000 | usd |
| CY2024Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-2498000 | usd |
| CY2023Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
-1561000 | usd |
| CY2024Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
95000 | usd |
| CY2023Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
282000 | usd |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
129000 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | usd |
| CY2024Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
-517000 | usd |
| CY2023Q1 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | usd |
| CY2024Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-17985000 | usd |
| CY2023Q1 | us-gaap |
Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
|
-26876000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-17985000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-17985000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-26876000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
|
-26876000 | usd |
| CY2024Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-17985000 | usd |
| CY2023Q1 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-26876000 | usd |
| CY2024Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.09 | |
| CY2024Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.09 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Basic
EarningsPerShareBasic
|
-0.15 | |
| CY2023Q1 | us-gaap |
Earnings Per Share Diluted
EarningsPerShareDiluted
|
-0.15 | |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
204955151 | shares |
| CY2024Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
204955151 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
|
184768983 | shares |
| CY2023Q1 | us-gaap |
Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
|
184768983 | shares |
| CY2022Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
5230000 | usd |
| CY2023Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
34000 | usd |
| CY2023Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2489000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26876000 | usd |
| CY2023Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-19123000 | usd |
| CY2023Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
-30584000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
18740000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
|
70000 | usd |
| CY2024Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
141000 | usd |
| CY2024Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
2360000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17985000 | usd |
| CY2024Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-17985000 | usd |
| CY2023Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-26876000 | usd |
| CY2024Q1 | us-gaap |
Depreciation
Depreciation
|
364000 | usd |
| CY2023Q1 | us-gaap |
Depreciation
Depreciation
|
398000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9011000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9011000 | usd |
| CY2024Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
129000 | usd |
| CY2023Q1 | us-gaap |
Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
|
0 | usd |
| CY2024Q1 | akba |
Contractual Arrangement Royalties Agreement Noncash Royalty Revenue
ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue
|
391000 | usd |
| CY2023Q1 | akba |
Contractual Arrangement Royalties Agreement Noncash Royalty Revenue
ContractualArrangementRoyaltiesAgreementNoncashRoyaltyRevenue
|
425000 | usd |
| CY2024Q1 | akba |
Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
|
0 | usd |
| CY2023Q1 | akba |
Noncash Research And Development Expense
NoncashResearchAndDevelopmentExpense
|
782000 | usd |
| CY2024Q1 | akba |
Noncash Interest Expense
NoncashInterestExpense
|
326000 | usd |
| CY2023Q1 | akba |
Noncash Interest Expense
NoncashInterestExpense
|
502000 | usd |
| CY2024Q1 | us-gaap |
Straight Line Rent
StraightLineRent
|
-1017000 | usd |
| CY2023Q1 | us-gaap |
Straight Line Rent
StraightLineRent
|
578000 | usd |
| CY2024Q1 | us-gaap |
Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
|
294000 | usd |
| CY2023Q1 | us-gaap |
Write Off Of Deferred Debt Issuance Cost
WriteOffOfDeferredDebtIssuanceCost
|
0 | usd |
| CY2024Q1 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
590000 | usd |
| CY2023Q1 | us-gaap |
Inventory Write Down
InventoryWriteDown
|
335000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2360000 | usd |
| CY2023Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
2489000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-12670000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-21553000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
4434000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Inventories
IncreaseDecreaseInInventories
|
-7347000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-1412000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-7378000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
613000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
2812000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-7501000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-9013000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-15045000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-25115000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
-731000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
|
651000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
695000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
|
-3738000 | usd |
| CY2024Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
-1600000 | usd |
| CY2023Q1 | us-gaap |
Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
|
573000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-19432000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-17538000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
37000000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
|
0 | usd |
| CY2024Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
750000 | usd |
| CY2023Q1 | us-gaap |
Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
|
0 | usd |
| CY2024Q1 | akba |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
18740000 | usd |
| CY2023Q1 | akba |
Proceeds From Issuance Of Common Stock Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts
|
0 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
70000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Plans
ProceedsFromStockPlans
|
34000 | usd |
| CY2024Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
141000 | usd |
| CY2023Q1 | us-gaap |
Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
|
0 | usd |
| CY2024Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
36726000 | usd |
| CY2023Q1 | us-gaap |
Repayments Of Debt
RepaymentsOfDebt
|
16000000 | usd |
| CY2024Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
18475000 | usd |
| CY2023Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
-15966000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-957000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-33504000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
44579000 | usd |
| CY2022Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
93169000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
43622000 | usd |
| CY2023Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
59665000 | usd |
| CY2024Q1 | akba |
Non Cash Financing Activities Issuance Of Warrants
NonCashFinancingActivitiesIssuanceOfWarrants
|
4846000 | usd |
| CY2023Q1 | akba |
Non Cash Financing Activities Issuance Of Warrants
NonCashFinancingActivitiesIssuanceOfWarrants
|
0 | usd |
| CY2024Q1 | akba |
Non Cash Financing Activities Unpaid Issuance Costs
NonCashFinancingActivitiesUnpaidIssuanceCosts
|
522000 | usd |
| CY2023Q1 | akba |
Non Cash Financing Activities Unpaid Issuance Costs
NonCashFinancingActivitiesUnpaidIssuanceCosts
|
0 | usd |
| CY2024Q1 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:10.27pt">NATURE OF BUSINESS</span><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Organization</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Akebia Therapeutics, Inc., referred to as </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Akebia</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> or the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">Company</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, was incorporated in the State of Delaware in 2007 and became a public company in 2014. Akebia is a fully integrated commercial-stage biopharmaceutical company committed to addressing patients' unmet needs. The Company's purpose is to better the life of each person impacted by kidney disease. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company has two products approved by the Food and Drug Administration, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">FDA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, in the United States, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">U.S.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> Vafseo® (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">HIF-PH,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> inhibitor. Vafseo (vadadustat) tablets is approved in the U.S. on March 27, 2024 for the treatment of anemia due to chronic kidney disease, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">CKD</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, in adults who have been receiving dialysis for at least three months. The Company intends to commercialize Vafseo in the U.S. with Vifor (International) Ltd. (now a part of CSL Limited), or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">CSL Vifor</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Auryxia</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:112%;position:relative;top:-3.5pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> (ferric citrate) is marketed for two indications: (i) the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">DD-CKD</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, and (ii) the treatment of iron deficiency anemia, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">IDA,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> in adult patients with non-dialysis chronic kidney disease, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline">NDD-CKD</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">. Auryxia will lose exclusivity in the U.S. in March 2025. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vafseo is also approved for the treatment of symptomatic anemia associated with CKD in the European Economic Area, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">EEA</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the United Kingdom, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">UK</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, Switzerland, Australia, South Korea and Taiwan in adult patients on chronic maintenance dialysis and in Japan for adult dialysis-dependent and non-dialysis patients. The Company will continue to support its partners in preparation to launch Vafseo in Europe, Taiwan and potentially other countries to pursue its goal of enabling broad access to Vafseo for patients globally.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Ferric citrate is also approved in Japan, and is marketed and sold by the Company's collaboration partner, as an oral treatment for the improvement of hyperphosphatemia in patients with CKD, including DD-CKD and NDD-CKD and for the treatment of adult patients with IDA under the trade name Riona (ferric citrate hydrate).</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Since its inception, the Company has devoted most of its resources to research and development, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">R&D</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, including its preclinical and clinical development activities, commercializing Auryxia and providing general and administrative support for these operations. The Company began recording revenue from the U.S. sales of Auryxia and revenue from sublicensing rights to Auryxia in Japan from the Company’s Japanese partners, Japan Tobacco, Inc. and its subsidiary Torii Pharmaceutical Co., Ltd., collectively, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">JT and Torii,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> in 2018. In addition, the Company continues to explore additional development opportunities to expand its pipeline and portfolio of novel therapeutics. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As of March 31, 2024, the Company had cash and cash equivalents of approximately $42.0 million. Based on its current operating plan, the Company believes that its cash resources and the cash the Company expects to generate from product, royalty, supply and license revenues will be sufficient to fund its current operating plan for at least twelve months from the filing of this Quarterly Report on Form 10-Q, or </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline">Form 10-Q</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. However, if the Company’s operating performance deteriorates significantly from the levels expected in the Company’s operating plan, it would affect the Company’s liquidity and its ability to continue as a going concern in the future. The Company expects to finance future cash needs through product and license, collaboration and other revenue, including royalties and revenue from supply agreements. If the Company believes its resources are insufficient to satisfy its liquidity requirements, it may seek to sell public or private equity, enter into new debt transactions, explore potential strategic transactions, consider other cash-generating or saving measures or a combination of these approaches or other strategic alternatives. There can be no assurance that the current operating plan will be achieved in the time frame anticipated by the Company or that its cash resources will fund its operating plan for the period of time anticipated by the Company, or that additional funding will be available on terms acceptable to the Company, or at all.</span></div> | |
| CY2024Q1 | akba |
Number Of Commercial Products
NumberOfCommercialProducts
|
2 | product |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
42000000 | usd |
| CY2024Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, revenue and expenses, classification of the expenses, assets and liabilities and the disclosure of contingent assets and liabilities as of and during the reported period. On an ongoing basis, management evaluates its estimates. Management bases its estimates and assumptions on historical experience when available and on various factors, including expected business and operational changes, sensitivity and volatility associated with the assumption that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of the assets and liabilities that are not readily apparent from other sources. In certain circumstances, management must apply significant judgment in this process. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management selects an amount that falls within that range of reasonable estimates. Although the Company regularly assesses these estimates, actual results could differ materially from these estimates. Changes in estimates are recorded in the period they become known.</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Significant estimates and judgments reflected in these unaudited condensed consolidated financial statements include, but are not limited to: accrued expenses, other long-term liabilities, product revenues, including various rebates, returns and reserves related to product sales, inventories, classification of expenses between cost of goods sold, R&D and selling, general and administrative, long-term assets, including the Company's right-of-use assets, intangible asset and goodwill.</span></div> | |
| CY2024Q1 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
41961000 | usd |
| CY2023Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
42925000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash
RestrictedCash
|
1661000 | usd |
| CY2023Q4 | us-gaap |
Restricted Cash
RestrictedCash
|
1654000 | usd |
| CY2024Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
43622000 | usd |
| CY2023Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
44579000 | usd |
| CY2024Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Credit Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents and accounts receivable are the only financial instruments that potentially subject the Company to concentrations of credit risk. The Company maintains cash accounts principally at two financial institutions in the U.S., which at times, may exceed the Federal Deposit Insurance Corporation's limits. The Company has not experienced any losses from cash balances in excess of the insurance limit. The Company's management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institutions where its cash is held. </span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company makes judgments as to its ability to collect outstanding receivables and provides an allowance for receivables when collection becomes doubtful. Provisions are made based upon a specific review of all significant outstanding receivables and the overall quality and age of those invoices not specifically reviewed as well as historical payment patterns and existing economic factors. The Company believes that credit risks associated with its customers and collaboration partners are not significant. The Company's allowance for credit losses was $0.6 million and $1.0 million as of March 31, 2024 and December 31, 2023, respectively. Write-offs for the three months ended March 31, 2024 were $0.5 million. There were no write-offs for the three months ended March 31, 2023. </span></div><div style="margin-bottom:6pt;margin-top:6pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Manufacturing and Distribution Risk</span></div><div style="margin-bottom:6pt;margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is dependent on third-party manufacturers, logistics company and distributors to supply products for commercial activities associated with its product and product candidates, as applicable. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply it with its requirements for the active pharmaceutical ingredients and formulated drugs related to the Company's product and product candidate activities. These activities, including the commercialization of Auryxia and Vafseo, could be adversely affected by a significant interruption in the supply of active pharmaceutical ingredients and formulated drugs or distribution of finished product to the market.</span></div> | |
| CY2024Q1 | akba |
Cash Number Of Financial Institutions Held Within
CashNumberOfFinancialInstitutionsHeldWithin
|
2 | financial_institution |
| CY2024Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
600000 | usd |
| CY2023Q4 | us-gaap |
Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
|
1000000 | usd |
| CY2024Q1 | us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
500000 | usd |
| CY2023 | us-gaap |
Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
|
0 | usd |
| CY2024Q1 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
11399000 | usd |
| CY2023Q4 | us-gaap |
Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
|
11394000 | usd |
| CY2024Q1 | us-gaap |
Inventory Net
InventoryNet
|
25532000 | usd |
| CY2023Q4 | us-gaap |
Inventory Net
InventoryNet
|
15691000 | usd |
| CY2024Q1 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
586000 | usd |
| CY2023Q4 | us-gaap |
Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
|
1143000 | usd |
| CY2024Q1 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
8154000 | usd |
| CY2023Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
9403000 | usd |
| CY2024Q1 | akba |
Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
|
33686000 | usd |
| CY2023Q4 | akba |
Inventory Net Current And Non Current
InventoryNetCurrentAndNonCurrent
|
25094000 | usd |
| CY2024Q1 | akba |
Inventory Recovery Of Write Downs
InventoryRecoveryOfWriteDowns
|
3700000 | usd |
| CY2024Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9000000 | usd |
| CY2023Q1 | us-gaap |
Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
|
9000000 | usd |
| CY2023Q4 | us-gaap |
Goodwill
Goodwill
|
59000000 | usd |
| CY2024Q1 | us-gaap |
Goodwill
Goodwill
|
59000000 | usd |
| CY2024Q1 | us-gaap |
Goodwill Impaired Accumulated Impairment Loss
GoodwillImpairedAccumulatedImpairmentLoss
|
0 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
|
14018000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense Current And Noncurrent
PrepaidExpenseCurrentAndNoncurrent
|
14489000 | usd |
| CY2024Q1 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
4813000 | usd |
| CY2023Q4 | us-gaap |
Other Assets Current
OtherAssetsCurrent
|
5754000 | usd |
| CY2024Q1 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
18831000 | usd |
| CY2023Q4 | us-gaap |
Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
|
20243000 | usd |
| CY2024Q1 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
8154000 | usd |
| CY2023Q4 | us-gaap |
Inventory Noncurrent
InventoryNoncurrent
|
9403000 | usd |
| CY2024Q1 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1661000 | usd |
| CY2023Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
1654000 | usd |
| CY2024Q1 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
1978000 | usd |
| CY2023Q4 | us-gaap |
Other Assets Miscellaneous Noncurrent
OtherAssetsMiscellaneousNoncurrent
|
1366000 | usd |
| CY2024Q1 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
11793000 | usd |
| CY2023Q4 | us-gaap |
Other Assets Noncurrent
OtherAssetsNoncurrent
|
12423000 | usd |
| CY2024Q1 | akba |
Capitalized Implementation Expense
CapitalizedImplementationExpense
|
600000 | usd |
| CY2023Q4 | akba |
Capitalized Implementation Expense
CapitalizedImplementationExpense
|
0 | usd |
| CY2024Q1 | us-gaap |
Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
|
0 | usd |
| CY2023Q1 | us-gaap |
Capitalized Computer Software Amortization1
CapitalizedComputerSoftwareAmortization1
|
0 | usd |
| CY2024Q1 | akba |
Accrued Product Revenue Allowances Current
AccruedProductRevenueAllowancesCurrent
|
13563000 | usd |
| CY2023Q4 | akba |
Accrued Product Revenue Allowances Current
AccruedProductRevenueAllowancesCurrent
|
22940000 | usd |
| CY2024Q1 | akba |
Accrued Product Revenue Return Reserves Current
AccruedProductRevenueReturnReservesCurrent
|
4516000 | usd |
| CY2023Q4 | akba |
Accrued Product Revenue Return Reserves Current
AccruedProductRevenueReturnReservesCurrent
|
5420000 | usd |
| CY2024Q1 | akba |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
253000 | usd |
| CY2023Q4 | akba |
Accrued Clinical Expenses Current
AccruedClinicalExpensesCurrent
|
328000 | usd |
| CY2024Q1 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
5817000 | usd |
| CY2023Q4 | us-gaap |
Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
|
8216000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
5071000 | usd |
| CY2023Q4 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
4491000 | usd |
| CY2024Q1 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
2568000 | usd |
| CY2023Q4 | us-gaap |
Accrued Royalties Current
AccruedRoyaltiesCurrent
|
3989000 | usd |
| CY2024Q1 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
2889000 | usd |
| CY2023Q4 | us-gaap |
Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
|
1909000 | usd |
| CY2024Q1 | akba |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
1676000 | usd |
| CY2023Q4 | akba |
Accrued Manufacturing Costs Current
AccruedManufacturingCostsCurrent
|
5555000 | usd |
| CY2024Q1 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
751000 | usd |
| CY2023Q4 | us-gaap |
Restructuring Reserve Current
RestructuringReserveCurrent
|
737000 | usd |
| CY2024Q1 | akba |
Long Term Purchase Commitment Termination Fee Current
LongTermPurchaseCommitmentTerminationFeeCurrent
|
10000000 | usd |
| CY2023Q4 | akba |
Long Term Purchase Commitment Termination Fee Current
LongTermPurchaseCommitmentTerminationFeeCurrent
|
7500000 | usd |
| CY2024Q1 | akba |
Contractual Arrangement Royalties Agreement Liability Current
ContractualArrangementRoyaltiesAgreementLiabilityCurrent
|
1994000 | usd |
| CY2023Q4 | akba |
Contractual Arrangement Royalties Agreement Liability Current
ContractualArrangementRoyaltiesAgreementLiabilityCurrent
|
2048000 | usd |
| CY2024Q1 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4812000 | usd |
| CY2023Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
4602000 | usd |
| CY2024Q1 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
53910000 | usd |
| CY2023Q4 | us-gaap |
Accrued Liabilities Current
AccruedLiabilitiesCurrent
|
67735000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
|
0 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
|
0 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
|
0 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
|
34010000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
|
1299000 | usd |
| CY2024Q1 | us-gaap |
Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
|
35309000 | usd |
| CY2024Q1 | us-gaap |
Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
|
5164000 | usd |
| CY2024Q1 | us-gaap |
Long Term Debt
LongTermDebt
|
30145000 | usd |
| CY2024Q1 | akba |
Valuation Allowances And Reserves Adjustments Related To Prior Period Sales
ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
|
-1572000 | usd |
| CY2024Q1 | us-gaap |
Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
|
22472000 | usd |
| CY2024Q1 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
20570000 | usd |
| CY2024Q1 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
3076923 | shares |
| CY2024Q1 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
1.30 | |
| CY2024Q1 | us-gaap |
Warrants And Rights Outstanding Term
WarrantsAndRightsOutstandingTerm
|
P8Y | |
| CY2024Q1 | us-gaap |
Derivative Liabilities
DerivativeLiabilities
|
5000000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
|
695000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
|
43296000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability
ContractWithCustomerLiability
|
43991000 | usd |
| CY2024Q1 | akba |
Contract With Customer Refund Liability Amortization Of Discount
ContractWithCustomerRefundLiabilityAmortizationOfDiscount
|
700000 | usd |
| CY2023Q1 | akba |
Contract With Customer Refund Liability Amortization Of Discount
ContractWithCustomerRefundLiabilityAmortizationOfDiscount
|
800000 | usd |
| CY2024Q1 | akba |
Contract With Customer Refund Liability Amortization Of Deferred Gain
ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain
|
900000 | usd |
| CY2023Q1 | akba |
Contract With Customer Refund Liability Amortization Of Deferred Gain
ContractWithCustomerRefundLiabilityAmortizationOfDeferredGain
|
1000000 | usd |
| CY2021Q1 | akba |
Contractual Arrangement Royalties Agreement Maximum Annual Royalty Payout Capacity
ContractualArrangementRoyaltiesAgreementMaximumAnnualRoyaltyPayoutCapacity
|
13000000 | usd |
| CY2021Q1 | akba |
Contractual Arrangement Royalties Agreement Percentage
ContractualArrangementRoyaltiesAgreementPercentage
|
0.85 | |
| CY2021Q1 | akba |
Contractual Arrangement Royalties Agreement Maximum Aggregate Royalty Payout Capacity
ContractualArrangementRoyaltiesAgreementMaximumAggregateRoyaltyPayoutCapacity
|
150000000 | usd |
| CY2021Q1 | akba |
Contractual Arrangement Royalties Agreement Liability Noncurrent
ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
|
44800000 | usd |
| CY2024Q1 | akba |
Contractual Arrangement Royalties Agreement Interest Rate Effective Percentage
ContractualArrangementRoyaltiesAgreementInterestRateEffectivePercentage
|
0 | |
| CY2024Q1 | us-gaap |
Payments For Royalties
PaymentsForRoyalties
|
400000 | usd |
| CY2024Q1 | akba |
Contractual Arrangement Royalties Agreement Liability Current
ContractualArrangementRoyaltiesAgreementLiabilityCurrent
|
1994000 | usd |
| CY2023Q4 | akba |
Contractual Arrangement Royalties Agreement Liability Current
ContractualArrangementRoyaltiesAgreementLiabilityCurrent
|
2048000 | usd |
| CY2024Q1 | akba |
Contractual Arrangement Royalties Agreement Liability Noncurrent
ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
|
53498000 | usd |
| CY2023Q4 | akba |
Contractual Arrangement Royalties Agreement Liability Noncurrent
ContractualArrangementRoyaltiesAgreementLiabilityNoncurrent
|
54013000 | usd |
| CY2024Q1 | akba |
Contractual Arrangement Royalties Agreement Liability
ContractualArrangementRoyaltiesAgreementLiability
|
55492000 | usd |
| CY2023Q4 | akba |
Contractual Arrangement Royalties Agreement Liability
ContractualArrangementRoyaltiesAgreementLiability
|
56061000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Remaining Lease Term
LesseeOperatingLeaseRemainingLeaseTerm
|
P2Y5M12D | |
| CY2024Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1200000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1800000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1400000 | usd |
| CY2023Q1 | us-gaap |
Operating Lease Payments
OperatingLeasePayments
|
1700000 | usd |
| CY2023 | us-gaap |
Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
|
-500000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
4308000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
|
5819000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
3613000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
13740000 | usd |
| CY2024Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
1033000 | usd |
| CY2024Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
12707000 | usd |
| CY2024Q1 | us-gaap |
Research And Development Arrangement Contract To Perform For Others Costs Incurred Gross
ResearchAndDevelopmentArrangementContractToPerformForOthersCostsIncurredGross
|
47900000 | usd |
| CY2023Q4 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
31514000 | usd |
| CY2024Q1 | us-gaap |
Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
|
13100000 | usd |
| CY2022Q4 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
38434000 | usd |
| CY2023Q1 | us-gaap |
Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
|
20488000 | usd |
| CY2023Q1 | akba |
Valuation Allowances And Reserves Adjustments Related To Prior Period Sales
ValuationAllowancesAndReservesAdjustmentsRelatedToPriorPeriodSales
|
-1980000 | usd |
| CY2023Q1 | us-gaap |
Valuation Allowances And Reserves Deductions
ValuationAllowancesAndReservesDeductions
|
25949000 | usd |
| CY2023Q1 | us-gaap |
Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
|
30993000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
0 | usd |
| CY2023Q1 | us-gaap |
Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
|
3738000 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
0 | usd |
| CY2024Q1 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
0 | usd |
| CY2023Q1 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
0 | usd |
| CY2023Q1 | us-gaap |
Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
|
0 | usd |
| CY2020Q2 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
175000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
350000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
350000000 | shares |
| CY2024Q1 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.00001 | |
| CY2024Q1 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
209454149 | shares |
| CY2024Q1 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
209454149 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
194582539 | shares |
| CY2023Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
194582539 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
25000000 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.00001 | |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2023Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | shares |
| CY2024Q1 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
0 | shares |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2400000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2500000 | usd |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
13312835 | shares |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
4.20 | |
| CY2023 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y3M7D | |
| CY2023Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
0 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
4088450 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
1.68 | |
| CY2024Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
280260 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
0.50 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
25074 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
13.67 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
218175 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
6.28 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
16877776 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
3.61 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P7Y8M8D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
5655000 | usd |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
7898693 | shares |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
5.94 | |
| CY2024Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
|
P6Y18D | |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
|
10000000 | usd |
| CY2024Q1 | us-gaap |
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
|
P3Y18D | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0390 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0423 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
|
0.0354 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
|
0.0357 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.1133 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.1425 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
|
1.0097 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
|
1.0216 | |
| CY2024Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2023Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
|
0 | |
| CY2024Q1 | akba |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value At Grant Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueAtGrantDate
|
1.46 | |
| CY2023Q1 | akba |
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Fair Value At Grant Date
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsFairValueAtGrantDate
|
0.52 | |
| CY2024Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2360000 | usd |
| CY2023Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
2489000 | usd |
| CY2024Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
27175778 | shares |
| CY2023Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
20573488 | shares |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
|
false | |
| CY2024Q1 | ecd |
Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
|
false | |
| CY2024Q1 | ecd |
Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
|
false |
